Betrapally Naga S, Gillevet Patrick M, Bajaj Jasmohan S
Microbiome Analysis Center, George Mason University, Manassas, Va.
Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, Va.
Transl Res. 2017 Jan;179:49-59. doi: 10.1016/j.trsl.2016.07.005. Epub 2016 Jul 15.
Gut microbiota changes are important in determining the occurrence and progression of chronic liver disease related to alcohol, nonalcoholic fatty liver disease, and cirrhosis. Specifically, the systemic inflammation, endotoxemia, and the vasodilation that leads to complications such as spontaneous bacterial peritonitis and hepatic encephalopathy could be related to the gut milieu. Given the poor prognosis of these events, their prevention and early management are essential. Microbiota may be an essential component of the gut milieu that can impact these clinical events, and the study of their composition and function in a culture-independent manner could help understand the prognosis. Recent human and animal studies have shown that the relative abundance and the functional changes of microbiota in the stool, colonic mucosa, and saliva have varying consequences on the presence and prognosis of chronic liver disease and cirrhosis. The impact of therapies on the microbiota is slowly being understood and will likely lead to a more targeted approach to gut microbiota modification in chronic liver disease and cirrhosis.
肠道微生物群的变化在决定与酒精相关的慢性肝病、非酒精性脂肪性肝病和肝硬化的发生及进展方面具有重要意义。具体而言,全身炎症、内毒素血症以及导致自发性细菌性腹膜炎和肝性脑病等并发症的血管舒张可能与肠道环境有关。鉴于这些情况预后较差,对其进行预防和早期管理至关重要。微生物群可能是肠道环境的一个重要组成部分,能够影响这些临床事件,以非培养方式研究其组成和功能有助于了解预后。最近的人类和动物研究表明,粪便、结肠黏膜和唾液中微生物群的相对丰度和功能变化对慢性肝病和肝硬化的存在及预后有不同影响。治疗对微生物群的影响正逐渐被了解,这可能会导致在慢性肝病和肝硬化中对肠道微生物群进行更有针对性的调节。